Biomedical Big Data Company GENALICE Now Able to Process a Complete Human DNA in Less Than 30 Minutes - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Biomedical Big Data Company GENALICE Now Able to Process a Complete Human DNA in Less Than 30 Minutes


Biomedical Big Data Company GENALICE Now Able to Process a Complete Human DNA in Less Than 30 Minutes

PR Newswire

HARDERWIJK, The Netherlands, May 28, 2014 /PRNewswire/ --

Today GENALICE proudly announced the planned release of an upgraded version of its Next-Generation Sequencing (NGS) DNA data processing software solution GENALICE MAP, at the European Society of Human Genetics conference in Milan later this week. Featuring the new 5-minute Variant Caller, the company is now capable of processing the DNA data of an entire human genome with 40x depth within 30 minutes on a commodity dual Intel Xeon E5 server.

The company commercializes its software in a turnkey appliance, the GENALICE VAULT. This all-in-one bioinformatics tool is preloaded with the company's breakthrough DNA processing solution GENALICE MAP. Hans Karten, CEO/CTO, explains: "The two key processing steps after DNA has been sequenced are short read alignment and variant calling. In our first release we only included the alignment part. We are extremely pleased to upgrade our software suite with our ultra-fast and highly accurate variant caller. Both steps normally take 1 to 2 days on a similar hardware configuration. By mastering both steps in less than 30 minutes now, we have created a processing pipeline that offers our customers spectacular benefits. Exome data or panels can be processed in near real-time.  Combining our speed and footprint reduction we are able to drive down the cost of processing and storing a full genome to less than $100 per year, while further improving the quality".

The company has collaborated with several scientific institutes to validate their pipeline. In the public domain GENALICE tested its product with well-known reference datasets like "Genome in a Bottle" and has used the highly recommended Genome Comparison & Analytic Testing (GCAT) tool from Bioplanet.com to directly compare the sensitivity and specificity with most commonly used conventional tools. The excellent results have been drafted in a white paper and GCAT report. Both can be found at the company's website in the product section under GENALICE MAP.

About GENALICE 

GENALICE is a privately owned, innovative biomedical big data company, based in the Netherlands. It designs and builds groundbreaking software solutions for cost effective and accurate DNA data processing and analysis on commodity hardware. Its mission is to save lives and improve the quality of life of people with complex DNA-related diseases, such as cancer. With state of the art technology GENALICE wants to make an important contribution to improved drug development, diagnosis and treatment.

http://www.genalice.com 

Twitter - YouTube - Facebook - Skype: GenaliceDNA

SOURCE GENALICE B.V.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document

Click here